Fact Source: Financial Supervisory Service DART / 2026-02-25
Disclosure Type: Submission of Audit Report
💡 3-Second Summary
Samsung Biologics has officially received an ‘Unqualified (Clean)’ audit opinion from its external auditor, verifying the reliability of its financial records. For the current fiscal year, consolidated revenue reached approximately KRW 4.56T and operating profit stood at KRW 2.07T, showing financial growth compared to the prior fiscal year.
📊 1. [Key Disclosure Content & Major Figures Summary]
- External Auditor & Audit Opinion: Audited by KPMG SAMJONG Accounting Corp., receiving an ‘Unqualified’ audit opinion for both consolidated and separate financial statements.
- Going Concern Uncertainty & Internal Accounting Control Status: Stated as ‘Not Applicable’ and ‘Unrecorded’, indicating no identified accounting risk factors.
- Key Consolidated Financials (KRW):
- Revenue: KRW 4,556,971,695,180 (Prior Year: KRW 3,497,145,675,782)
- Operating Profit: KRW 2,069,221,266,630 (Prior Year: KRW 1,321,366,380,588)
- Net Income: KRW 1,784,352,060,593 (Prior Year: KRW 1,083,315,885,986)
- Key Separate Financials (KRW):
- Revenue: KRW 4,556,971,695,180
- Operating Profit: KRW 2,068,092,839,427
- Net Income: KRW 1,586,186,963,312
- Other Major Operational Structural Updates:
- The number of consolidated subsidiaries decreased from 14 to 1, and the number of major subsidiaries decreased from 1 to 0 compared to the prior year.
- Capital impairment ratio is not applicable; no description of embezzlement or breach of trust.
- The disclosure does not state specific reasons for the change in earnings.
- Investor Notice: These financial statements are subject to final statutory approval at the upcoming general shareholders’ meeting post the audit report receipt date (2026-02-25), and figures may change during the approval process.
📈 2. [Expert View: What This Disclosure Means for Investors]
This filing indicates that the accounting integrity of Samsung Biologics’ fiscal financial statements has been validated by its external auditor. Crucial fundamental metrics, notably a consolidated operating profit of approximately KRW 2.07T, demonstrate notable expansion compared to the prior fiscal year (approx. KRW 1.32T). Securing an ‘Unqualified’ opinion suggests that valuation uncertainties related to fiscal accounting are diminished.
On the balance sheet side, consolidated total assets and total equity decreased compared to the prior year, yet critical warning indicators—such as accounting internal control deficiencies or material uncertainties regarding going concern status—remain completely absent. A distinctive fact to analyze is the reduction in consolidated subsidiaries from 14 down to 1. The original disclosure text does not clarify the specific drivers behind these structural and performance shifts. Given that minor numbers adjustments remain possible until the final general shareholders’ meeting approval, investors should monitor the confirmed financial totals and analyze the potential impact of the consolidated scope adjustment.
📝 Editor’s Comment (by K-STOCK Editor)
The submission of the fiscal audit report by Samsung Biologics serves as confirmation that its operational performance metrics are backed by verified regulatory compliance. Landing a clean ‘Unqualified’ bill of health from KPMG Samjong across both consolidated and separate ledgers anchors the headline milestone of surpassing KRW 2T in consolidated operating profit. Governance indicators remain clear, with no issues triggered concerning internal financial control systems or corporate compliance matters. The steep decline in consolidated subsidiaries down to a single entity introduces a structural parameter that may carry a potential impact on future reporting lines, making it advisable for long-term investors to look beyond day-to-day fluctuations and await the finalized statements post the general shareholders’ meeting.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
